Coronavirus Update: Lilly’s Antibody Plus Remdesivir Trial Abandoned
Other Lilly and NIH Studies Continue
Combination of antibody therapy and Gilead's Veklury fails to show potential in patients with advanced disease.
You may also be interested in...
The price of the antibody monotherapy for COVID-19 will be $1,250 per vial for wealthy countries. CEO David Ricks outlined the company's guidelines for pricing and distributing a limited supply.
US FDA will hold 10 December advisory committee on Pfizer/BioNTech's just-filed application; the WHO issued a recommendation against Gilead's Veklury for hospitalized patients.
Board directors appointed at Athersys, Trillium Therapeutics and Viatris